Genmab A/S Sponsored ADR $GMAB Stock Position Lowered by Signaturefd LLC

Signaturefd LLC lowered its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 13.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,124 shares of the company’s stock after selling 1,400 shares during the quarter. Signaturefd LLC’s holdings in Genmab A/S were worth $188,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Foresight Group Ltd Liability Partnership bought a new position in Genmab A/S during the first quarter valued at about $954,000. Vident Advisory LLC bought a new position in Genmab A/S during the first quarter valued at about $242,000. GAMMA Investing LLC boosted its stake in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock valued at $656,000 after buying an additional 31,343 shares in the last quarter. Fifth Third Bancorp boosted its stake in Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock valued at $825,000 after buying an additional 6,015 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in Genmab A/S by 377.5% during the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock valued at $77,000 after buying an additional 2,941 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Up 1.1%

Shares of NASDAQ:GMAB opened at $32.12 on Friday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $32.24. The business has a fifty day simple moving average of $25.64 and a 200 day simple moving average of $22.33. The firm has a market cap of $20.61 billion, a price-to-earnings ratio of 16.14, a P/E/G ratio of 1.80 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GMAB shares. Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Tuesday, September 23rd. HC Wainwright raised their price objective on Genmab A/S from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $40.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.